1. "2017"
  2. "Melanoma Disease Management Team"
  3. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (48)
  2. Meeting Abstract (18)
  3. Book Section (2)
Groups
  1. Department of Medicine (68)
  2. Melanoma Disease Management Team (68)
  3. Solid Tumor Oncology Division (68)
  4. Melanoma and Immunotherapeutics Service (55)
  5. GSK Faculty (37)
  6. Hematologic Malignancies, Division of (22)

More Groups

People
  1. Michael Postow (39)
  2. Jedd Wolchok (24)
  3. Alexander Shoushtari (16)
  4. Paul Chapman (10)
  5. Christopher Barker (9)
  6. Katherine Panageas (8)

More People

Years
  1. 2017 (68)
Publications
  1. Journal of Clinical Oncology (10)
  2. Journal for ImmunoTherapy of Cancer (8)
  3. Annals of Oncology (4)
  4. International Journal of Radiation Oncology, Biology, Physics (3)
  5. Journal of Translational Medicine (3)
  6. Lancet Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. Biomed Central Ltd (11)
  3. Elsevier Inc. (7)
  4. Lippincott Williams & Wilkins (5)
  5. Oxford University Press (5)
  6. Elsevier Science, Inc. (4)

More Publishers

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204
    Meeting Abstract

    Tawbi, H. A. H.; Forsyth, P. A. J.; Algazi, A. P.; Hamid, O.; Hodi, F. S.; Moschos, S. J.; Khushalani, N. I.; Gonzalez, R.; Lao, C. D.; Postow, M. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D)
    Meeting Abstract

    Schuler, M. H.; Ascierto, P. A.; De Vos, F. Y. F. L.; Postow, M. A.; Van Herpen, C. M. L.; Carlin, M. S.; Sosman, J. A.; Berking, C.; Long, G. V.; Weise, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and immunologic variables associated with outcomes following combination ipilimumab and nivolumab immunotherapy in melanoma
    Meeting Abstract

    Rosner, S.; Kwong, E.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Preliminary results from a single-arm, phase II study assessing the efficacy of pembrolizumab plus radiotherapy in metastatic triple negative breast cancer
    Meeting Abstract

    Ho, A.; Barker, C. A.; Gucalp, A.; Lebron-Zapata, L.; Wen, Y. H.; Phung, A.; Wilgucki, M.; Henrich, M.; Arnold, B.; Patil, S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors
    Meeting Abstract

    Friedman, C. F.; Wolchok, J. D.; Postow, M. A.; Shoushtari, A. N.; Callahan, M. K.; Momtaz, P.; Chapman, P. B.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Monotherapy dose escalation clinical and translational data from first-in-human study in advanced solid tumors of IPI-549, an oral, selective, PI3K-gamma inhibitor targeting tumor macrophages
    Meeting Abstract

    Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Ribas, A.; Brail, L.; Pearlberg, J.; Mahabhashyam, S.; Lee, L.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
    Meeting Abstract

    Budhu, S.; Giese, R.; De Henau, O.; Zappasodi, R.; Campesato, L. F.; Gupta, A.; Barker, C.; Freimark, B.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Meeting Abstract

    Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save